Phillips-Medisize Corp., a global outsource provider of design and manufacturing services to the medical device and diagnostics, drug delivery, and commercial markets, has signed a significant supply deal with leading diabetes treatment company Sanofi SA.
The agreement will see Hudson, Wis.-based Phillips-Medisize supply components for a new insulin pen, and has led to an expansion of 64,500 square feet to its plant in Kontiolahti, Finland.
The disposable insulin pen, made to meet the demands of the Japanese market, is designed to deliver the drug lixisenatide to patients. The manufacturing process will involve injection molding, assembly and tray handling robots, as well as testing and measuring processes. The final pen assembly will be launched by Sanofi in Frankfurt, Germany.
The deal between Phillips-Medisize and Sanofi highlights their long-term business relationship along with Phillips-Medisize's expertise in assembly technology, the companies said.
Phillips-Medisize president and CEO, Matt Jennings says of the deal: "This agreement confirms our in-house tooling and automation expertise, combined with excellent project management capabilities are highly valued by our customers. We will continue to develop our competency to offer them an even quicker service for their drug delivery device projects and are delighted to contribute to the rapid growth of the Sanofi diabetes treatment business."
Phillips-Medisize currently has annual sales of over $500 million, the majority of which comes from drug delivery, medical device, primary pharmaceutical packaging and diagnostic products such as disposable insulin pens.
